Clinical experience with L-asparaginase.
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001215:Asparaginase / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001774:Blood Chemical Analysis; D001806:Blood Urea Nitrogen; D001835:Body Weight; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D002784:Cholesterol / Q000097:blood; D004342:Drug Hypersensitivity / Q000209:etiology; D004487:Edema / Q000139:chemically induced; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D006801:Humans; D007945:Leukemia, Lymphoid / Q000097:blood / Q000188:drug therapy*; D008297:Male; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D000970:Antineoplastic Agents; D002784:Cholesterol; D001215:Asparaginase